Cytosorbents (CTSO) Net Equity Issued and Repurchased (2012 - 2024)

Cytosorbents' (CTSO) quarterly Net Equity Issued and Repurchased came in at -$238.0 in Q2 2024, down 100.45% on a QoQ basis from $53238.0 in Q1 2024.

Cytosorbents (CTSO) Net Equity Issued and Repurchased (2012 - 2024) Analysis & Trends

Cytosorbents (CTSO) has 4 years of Net Equity Issued and Repurchased data on file, last reported at -$238.0 in Q2 2024.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$238.0 in Q2 2024, while the trailing twelve-month figure through Sep 2024 was $694733.0 (changed N/A YoY) and the FY2023 annual result came in at $4.5 million, changed N/A from the prior year.
Net Equity Issued and Repurchased retreated to -$238.0 in Q2 2024, from $53238.0 in the prior quarter.
In the past five years, Net Equity Issued and Repurchased ranged from a high of $641733.0 in Q1 2023 to a low of -$238.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Abbott Laboratories	199.44 Bn	193.84 Bn	7.27 Bn	-
2	Stryker	127.32 Bn	123.85 Bn	4.50 Bn	-
3	Medtronic	118.87 Bn	109.65 Bn	6.41 Bn	97.00 Mn
4	Boston Scientific	73.47 Bn	72.93 Bn	3.85 Bn	-
5	Edwards Lifesciences	51.90 Bn	47.65 Bn	1.35 Bn	-
6	Dexcom	34.30 Bn	32.36 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.74 Bn	31.63 Bn	2.18 Bn	-
8	Koninklijke Philips	26.35 Bn	23.03 Bn	4.55 Bn	-
9	Steris	23.05 Bn	22.56 Bn	684.20 Mn	-
10	Cytosorbents	21.98 Mn	17.56 Mn	7.05 Mn	-

Download Data